Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
51 hedge funds and large institutions have $87.1M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 4 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 50 → 51 (+1)
18% less capital invested
Capital invested by funds: $107M → $87.1M (-$19.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$6.44M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$3.61M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
+$1.04M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$733K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$522K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.94M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$2.66M |
| 3 |
JP Morgan Chase
New York
|
-$218K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$206K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$126K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $39 | -$29.8K | -4,631 | -100% |
|
52
Renaissance Technologies
New York
| – | -$115K | -15,700 | Closed |
|
|
53
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$126K | -15,488 | Closed |
|
|
MIM
54
MetLife Investment Management
Whippany,
New Jersey
| – | -$65.6K | -8,932 | Closed |
|
|
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$6.8K | -926 | Closed |
|
LBPH Hedge Fund Activity: Q3 2023 in Review
51 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q3 2023, worth a combined $87.1M — down 18% from $107M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LBPH positions and 4 closed out — a net gain of 1 holder — while 19 added to existing stakes and 14 trimmed.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $6.44M. The largest seller was Fidelity Investments, cutting an estimated $2.94M.
- 51 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q3 2023, up from 50 in Q2 2023.
- Funds reported $87.1M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q3 2023, down 18% quarter-over-quarter.
- 5 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q3 2023 and 4 closed out, a net change of +1 holder.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q3 2023 was Polar Capital Holdings, an estimated $6.44M added.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q3 2023 was Fidelity Investments, an estimated $2.94M sold.
Based on aggregated 13F filings for Q3 2023.